Significant Accounting Policies (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|---|
Mar. 31, 2026 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Franchisor Disclosure [Line Items] | ||||||
| Off-balance sheet concentrations of credit risk | $ 0 | $ 0 | $ 0 | |||
| Equity securities without readily determinable fair value, impairment loss | 0 | $ 0 | ||||
| Restricted cash | 3,100,000 | 3,100,000 | 3,100,000 | |||
| Research and development expense due to cost share payments to related party | $ 97,019,000 | $ 102,696,000 | 200,865,000 | $ 218,923,000 | ||
| AVLAYAH | ||||||
| Franchisor Disclosure [Line Items] | ||||||
| Research and development expense due to cost share payments to related party | $ 12,600,000 | |||||
| Royalty Pharma | Royalty Agreement | ||||||
| Franchisor Disclosure [Line Items] | ||||||
| Authorized funding | $ 275,000,000.0 | |||||
| Royalty rate | 9.25% | |||||
| Proceeds received | $ 200,000,000.0 | |||||
| X | ||||||||||
- Definition Concentration Risk, Credit Risk, Financial Instruments, Off-Balance Sheet Risk, Amount No definition available.
|
| X | ||||||||||
- Definition Royalty Funding Arrangement, Authorized Funding No definition available.
|
| X | ||||||||||
- Definition Royalty Funding Arrangement, Royalty Rate No definition available.
|
| X | ||||||||||
- Definition Amount of impairment loss on investment in equity security without readily determinable fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of cash and cash equivalent restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|